A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression.

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL EClinicalMedicine Pub Date : 2024-08-16 eCollection Date: 2024-09-01 DOI:10.1016/j.eclinm.2024.102780
Ifigeneia Mavranezouli, Odette Megnin-Viggars, Hugo Pedder, Nicky J Welton, Sofia Dias, Edward Watkins, Neil Nixon, Caitlin H Daly, Edna Keeney, Hilary Eadon, Deborah M Caldwell, Katriona J M O'Donoghue, Sarah Stockton, Stephanie Arnold, James Thomas, Navneet Kapur, Stephen Pilling
{"title":"A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression.","authors":"Ifigeneia Mavranezouli, Odette Megnin-Viggars, Hugo Pedder, Nicky J Welton, Sofia Dias, Edward Watkins, Neil Nixon, Caitlin H Daly, Edna Keeney, Hilary Eadon, Deborah M Caldwell, Katriona J M O'Donoghue, Sarah Stockton, Stephanie Arnold, James Thomas, Navneet Kapur, Stephen Pilling","doi":"10.1016/j.eclinm.2024.102780","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Various effective treatments for depression exist. We aimed to identify the most effective first-line treatments for new episodes of less and more severe depression (defined by depression scale cut-off scores), to update NICE guidance on the management of Depression in Adults in England.</p><p><strong>Methods: </strong>Systematic review and network meta-analysis of randomised controlled trials (RCTs) published up to June 2020 (PROSPERO registration number CRD42019151328). We analysed interventions by class and individually. The primary efficacy outcome was depressive symptom change (expressed as standardised mean difference [SMD]). The review for this outcome was updated in November 2023.</p><p><strong>Findings: </strong>We included 676 RCTs, 105,477 participants and 63 treatment classes. For less severe depression, group cognitive/cognitive behavioural therapy (CT/CBT) class was efficacious versus treatment as usual [TAU], the reference treatment for this population [SMD -1.01 (95% Credible Interval [CrI] -1.76; -0.06)]. For more severe depression, efficacious classes versus pill placebo (reference treatment for this population) included combined individual CT/CBT with antidepressants [-1.18 (-2.07; -0.44)], individual behavioural therapies [-0.86 (-1.65; -0.16)], combined light therapy with antidepressants [-0.86 (-1.59; -0.12)], combined acupuncture with antidepressants [-0.78 (-1.12; -0.44)], individual CT/CBT [-0.78 (-1.42; -0.33)], mirtazapine [-0.35 (-0.48; -0.22)], serotonin and norepinephrine reuptake inhibitors [-0.32 (-0.43; -0.22)], tricyclic antidepressants [-0.29 (-0.50; -0.05)], and selective serotonin reuptake inhibitors [-0.24 (-0.32; -0.16)]. Additional treatments showed evidence of efficacy at the intervention level. Evidence for less and more severe depression was of low and low-to-moderate quality, respectively. In the 2023 update, group yoga and self-help without support emerged as efficacious for less severe depression. For more severe depression, combined group exercise with antidepressants emerged as efficacious, whereas combined light therapy with antidepressants failed to remain efficacious.</p><p><strong>Interpretation: </strong>Group CT/CBT (and possibly group yoga and self-help) appears efficacious in less severe depression, whereas antidepressants do not show evidence of effect. Combined antidepressants with individual CT/CBT, acupuncture and, possibly, group exercise, individual psychological therapies (behavioural therapies, CT/CBT) alone, and antidepressants alone appear efficacious in more severe depression. Quality of evidence, cost-effectiveness, applicability and implementation issues also need to be considered when formulating clinical practice recommendations.</p><p><strong>Funding: </strong>National Institute for Health and Care Excellence.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377144/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.102780","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Various effective treatments for depression exist. We aimed to identify the most effective first-line treatments for new episodes of less and more severe depression (defined by depression scale cut-off scores), to update NICE guidance on the management of Depression in Adults in England.

Methods: Systematic review and network meta-analysis of randomised controlled trials (RCTs) published up to June 2020 (PROSPERO registration number CRD42019151328). We analysed interventions by class and individually. The primary efficacy outcome was depressive symptom change (expressed as standardised mean difference [SMD]). The review for this outcome was updated in November 2023.

Findings: We included 676 RCTs, 105,477 participants and 63 treatment classes. For less severe depression, group cognitive/cognitive behavioural therapy (CT/CBT) class was efficacious versus treatment as usual [TAU], the reference treatment for this population [SMD -1.01 (95% Credible Interval [CrI] -1.76; -0.06)]. For more severe depression, efficacious classes versus pill placebo (reference treatment for this population) included combined individual CT/CBT with antidepressants [-1.18 (-2.07; -0.44)], individual behavioural therapies [-0.86 (-1.65; -0.16)], combined light therapy with antidepressants [-0.86 (-1.59; -0.12)], combined acupuncture with antidepressants [-0.78 (-1.12; -0.44)], individual CT/CBT [-0.78 (-1.42; -0.33)], mirtazapine [-0.35 (-0.48; -0.22)], serotonin and norepinephrine reuptake inhibitors [-0.32 (-0.43; -0.22)], tricyclic antidepressants [-0.29 (-0.50; -0.05)], and selective serotonin reuptake inhibitors [-0.24 (-0.32; -0.16)]. Additional treatments showed evidence of efficacy at the intervention level. Evidence for less and more severe depression was of low and low-to-moderate quality, respectively. In the 2023 update, group yoga and self-help without support emerged as efficacious for less severe depression. For more severe depression, combined group exercise with antidepressants emerged as efficacious, whereas combined light therapy with antidepressants failed to remain efficacious.

Interpretation: Group CT/CBT (and possibly group yoga and self-help) appears efficacious in less severe depression, whereas antidepressants do not show evidence of effect. Combined antidepressants with individual CT/CBT, acupuncture and, possibly, group exercise, individual psychological therapies (behavioural therapies, CT/CBT) alone, and antidepressants alone appear efficacious in more severe depression. Quality of evidence, cost-effectiveness, applicability and implementation issues also need to be considered when formulating clinical practice recommendations.

Funding: National Institute for Health and Care Excellence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对新发抑郁症成人的心理、社会心理、药物、物理和综合治疗方法的系统综述和网络荟萃分析。
背景:抑郁症有多种有效的治疗方法。我们旨在确定针对新发轻度和重度抑郁症(根据抑郁量表截断分数定义)最有效的一线治疗方法,以更新英国成人抑郁症管理 NICE 指南:对截至 2020 年 6 月发布的随机对照试验 (RCT) 进行系统回顾和网络荟萃分析(PROSPERO 注册号 CRD42019151328)。我们按类别和个体对干预措施进行了分析。主要疗效结果是抑郁症状变化(以标准化平均差 [SMD] 表示)。对这一结果的综述于2023年11月进行了更新:我们纳入了 676 项 RCT、105,477 名参与者和 63 个治疗类别。对于不太严重的抑郁症患者,团体认知/认知行为疗法(CT/CBT)与通常治疗[TAU](该人群的参考治疗方法)相比具有疗效[SMD-1.01(95%可信区间[CrI]-1.76;-0.06)]。对于更严重的抑郁症患者,与药片安慰剂(该人群的参考治疗)相比,疗效较好的治疗类别包括:联合个体 CT/CBT 与抗抑郁药[-1.18 (-2.07; -0.44)]、个体行为疗法[-0.86 (-1.65; -0.16)]、联合光疗与抗抑郁药[-0.86 (-1.59; -0.12)]、联合针灸与抗抑郁药[-0.78(-1.12;-0.44)]、个体 CT/CBT [-0.78(-1.42;-0.33)]、米氮平[-0.35(-0.48;-0.22)]、血清素和去甲肾上腺素再摄取抑制剂[-0.32(-0.43;-0.22)]、三环类抗抑郁药[-0.29(-0.50;-0.05)]和选择性血清素再摄取抑制剂[-0.24(-0.32;-0.16)]。其他治疗在干预水平上也显示出疗效。针对轻度和重度抑郁症的证据分别为低质量和低至中等质量。在2023年的更新中,团体瑜伽和无支持自助疗法对较轻抑郁症有效。对于较严重的抑郁症患者,联合团体运动和抗抑郁药物具有疗效,而联合光疗和抗抑郁药物则未能保持疗效:小组 CT/CBT(可能还有小组瑜伽和自助)对较轻的抑郁症有疗效,而抗抑郁药物则没有显示出疗效。对于较严重的抑郁症患者,联合使用抗抑郁药与个体 CT/CBT、针灸以及可能的集体运动,单独使用个体心理疗法(行为疗法、CT/CBT),以及单独使用抗抑郁药似乎都有疗效。在制定临床实践建议时,还需要考虑证据质量、成本效益、适用性和实施问题:国家健康与护理卓越研究所。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
期刊最新文献
Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis. CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial. Diagnostic performance of deep learning for infectious keratitis: a systematic review and meta-analysis. Gut microbiota in women with polycystic ovary syndrome: an individual based analysis of publicly available data. The global burden of enteric fever, 2017-2021: a systematic analysis from the global burden of disease study 2021.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1